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PATIENTS’ RIGHT TO CHOOSE; THE RIGHT-TO-TRY LAW 
MOVEMENT 
Implementation of right-to-try laws has swiftly increased among states all across the 
country. Currently, twenty-four states have signed right-to-try laws into effect, a number which 
is projected to grow in the near future.1 Right-to-try laws purport to give terminally ill patients 
the right to receive an “experimental new drug treatment,” meaning that the drug has not 
received Food and Drug Administration (FDA) approval.2 Proponents of right to try adamantly 
suggest patients and their physicians should be the one to decide whether or not a patient 
receives access to experimental drug treatment, not the government. But as many states begin to 
embrace right-try-laws, critics see it as a direct attack on the FDA regulations designed to protect 
patients, begging the question of whether the patient or the FDA should be the final decision 
maker when it comes to experimental drug treatments.3 And who is best suited to provide 
regulatory oversight to ensure patient safety.  
Birth of the Right-to-Try Law Movement 
Proponents of right-to-try laws claim access to investigational drugs through current FDA 
regulations is a time consuming process that requires approval through participation in a clinical 
trial or the expanded access provision.4 Time, however, is something these patients do not have. 
Each day without a viable course of treatment is another day detracted from their lives. In an 
effort to address public outcry for faster access to experimental drug treatment the state right-to-
try law movement was born.  
The rapid increase in these laws can be attributed to the series of publicized stories from 
terminally ill patients about their struggle to receive treatment. A perfect example of this is the 
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story of Jenn McNary.5 Ms. McNary is a mother of two boys, both diagnosed with Duchenne 
Muscular Dystrophy, a debilitating disease that leads to muscle degeneration.6 One of Ms. 
McNary’s sons was able to participate in an FDA approved clinical trial for a drug that could 
transform his disorder into a milder form of muscular dystrophy called Becker’s.7 While one 
son’s health significantly improved, she watched her other son’s health deteriorate.8 Ms. McNary 
described the ordeal, saying, “having a child that is dying is the most painful thing in the 
world… [and] the only thing that is more painful is having a child that is dying and knowing 
there is a drug that could help them, and not being able to have access to it. It’s a crime.”9  
Kianna Karnes, a 41-year-old mother of four, who was diagnosed with kidney cancer, has 
a similar story.10 The FDA denied her approval to participate in clinical trials for new 
investigational drugs that had potential to be a sustainable course of treatment for her disease, 
given the progression of her cancer.11 Eager to save his daughter, Ms. Karnes’s father sought 
approval through the FDA’s compassionate use process.12 Sadly, Ms. Karnes died the same day 
her compassionate use request was approved.13 The McNary and Karnes’ stories are just two of 
several cited by supporters of right-to-try laws to push for statewide implementation.  As social 
media platforms generate more public awareness of stories like Ms. McNary and Ms. Karnes, 
policy makers began to shift their focus to patient autonomy through state right-to-try laws.14  
Power struggle: State vs. Federal Oversight 
States do not have the power to bypass FDA regulations, as it would exceed the power 
granted to the states under federalism.  But if states were allowed to bypass the FDA’s decision-
making power, states would have show they would be able to provide the necessary level of 
oversight that comes with monitoring patients decision to use experimental treatment. Currently, 
right-to-try laws emphasize patient autonomy, but fall short of patient protection; something 
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much needed to protect this vulnerable group from harm. States ultimately fail to show that 
patients and their physicians can handle this type of power and instead highlight a new set of 
problems to follow if these laws were given legally effective power under state level authority. 
But, the right-to try law movement has rekindled the notion of patient autonomy and forced the 
FDA to revamp its expanded access application for faster patient access. 
State Right-to-Try Laws promote patient autonomy, but fall short of patient protection 
Critics of right-to-try laws argue that these laws would leave a number of unanswered 
legal questions.15 For example, if an insurer is not legally required to cover the cost of the 
investigational drug/product, patients may be expected to cover the cost themselves.16 Further, 
patients may need legal assistance when signing any potential additional consent forms required 
by the state.17 More importantly, the safety of patients who use these experimental drugs may be 
at risk if doctors and manufacturers are shielded from liability. 18 Many of these issues are 
already presented in some state right-to-try laws. For instance, both the New Jersey bill and 
Minnesota law clearly focus on patient autonomy, yet they leave many unanswered questions. 
Minnesota’s right-to-try law defines who qualifies to receive the drug, what an 
investigational drug/biological product is, and what it means to be terminally ill under the 
provision. 19 A patient qualifies to receive access to an investigational drug, biological product, 
or device once a physician has documented in writing that the patient has met all of the following 
requirements:20 
 (1) has a terminal illness; (2) has, in consultation with a physician 
considered all other treatment options currently approved by the FDA; (3) 
has been given a prescription or recommendation by a physician for an 
investigational drug, biological product, or device; and (4) has given 
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informed consent, in writing, for the use of the investigational drug, 
biological product, or device, or if the patient is under the age of 18, or 
lacks the mental capacity to provide informed consent, a parent or legal 
guardian has given informed consent, in writing, on behalf of the patient.21 
The Minnesota law gives the manufacturer the option of making its investigational drug, 
biological product, or device available to eligible patients under this section.22 A manufacturer 
can also provide the drug or biological product free of cost to the patient, or require the patient to 
pay the costs associated with the manufacturing of the product.23A patient’s health insurance 
provider is not required to cover the cost associated with the investigation drug or biologic 
product, meaning patients may be left with high medical bills.24 Although offering terminally ill 
patients an experimental drug free of charge is praiseworthy, this provision would also give 
manufacturers too much discretion in drug pricing. Without proper oversight, manufacturers 
have the potential to inflate the cost associated with the production of the drug and take 
advantage of this distressed group.  
New Jersey’s proposed right-to-try law, Bill No. 3474, includes a policy statement that 
asserts, it is a patient’s fundamental right to have access to these investigational drugs.25 The bill 
states:  
the standards of the United States [FDA] for the use of investigational 
drugs, biological devices…may deny the benefits of potentially life-saving 
treatments to patients who have a terminal illness. Patients who are 
terminally ill have a fundamental right to attempt to pursue the preservation 
of their lives by accessing available investigational drugs, biological 
products, and devices.26 
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 Similar to the Michigan right-to-try law, the New Jersey bill also contains some 
discrepancies.  For example, in one section of the bill it states, “a government medical assistance 
program or private health insurer may, but is not required to, provide coverage for the cost of an 
investigational drug, biological product, or device.”27 However, another section of the bill states 
“government medical assistance programs and private health insurers would not be required to… 
but private insurers would be permitted to provide coverage if they so choose.”28 Therefore, the 
conflicting language makes it unclear if both a government assistance program and private 
insurer can cover the cost of the treatment, or only the private insurer. 
 These right-to-try laws also each have their own definition of certain terms that can leave 
a lot of the decision making up to interpretation. For instance, under the Minnesota statute, 
terminal illness is defined as “a condition or illness which, to a reasonable degree of medical 
probability, is not considered reversible and even with the administration of current FDA-
approved and available treatments and the administration of life-sustaining procedures will soon 
result in death.”29 The words “soon result in death” are not further clarified and given a 
physician’s expertise and discussion with a patient, each physician may have a different take on 
what is soon under the circumstances.   
Although these laws often state that the new drug has to have successfully completed 
phase I of the FDA clinical trial investigational drug approval process as a requirement for 
access, they lack proper party accountability.30  Under the Minnesota statute, healthcare 
providers are not liable for harm done to a patient as a result of using the experimental drug 
treatment, as long as the health care provider or entity has complied with the terms of the statute 
provisions.31 When physicians and manufacturers are not held liable for harm caused to patients, 
patient safety is at risk. Michigan and Colorado right to-try-laws explicitly state that a patient’s 
5
Maxwell: Patient's Right to Choose; The Right-To-Try Law Movement
Published by eRepository @ Seton Hall, 2016
Jessica M. Maxwell 
Health Law Outlook Spring 2016-Final Draft 
 6 
insurer does not have to cover cost associated with any complication that may arise as a result of 
receiving the investigational drug treatment.32 As seen under the Minnesota provision, these 
types of laws would allow manufacturers and treating physicians to escape harm caused to a 
patient as result of the investigational treatment.  By also suggesting insurers are allowed to not 
cover cost associated with complications suffered by patients, individuals would be placed at a 
higher risk of harm, especially because patients are unlikely to be able to pay the cost to receive 
the necessary treatment out of pocket.   
Some states, however, have chosen to take the opposite approach to right-to-try laws. 
California governor, Jerry Brown chose to go against the right-to-try law movement and vetoed 
California’s right-to-try bill after it passed legislation. 33 Although, this is the less popular route, 
Governor Brown’s justification for doing so is commendable. Instead of caving into the pressure 
of public scrutiny, he recognized that the FDA was the appropriate authority to grant access to 
experiment treatment. The governor has stated, “patients with life threatening conditions should 
be able to try experimental drugs, [but]…before authorizing an alternative state pathway…we 
should give this federal expedited process a chance to work.”34 Governor Brown is referring to 
the proposed changes to the FDA’s expand access provision that would shorten the application 
process for experimental drug access for individual patients.35  
FDA Expanded Access Provision: Revamping “Compassionate Use” for Faster Access 
The goal of the FDA’s expand access provision, commonly known as “compassionate 
use,” is to make drugs available to patients with serious diseases or conditions when there is no 
comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease 
or condition.36 Therefore, the compassionate use provision is designed to accomplish the same 
goal as the one stated under right-to-try law, patient access.  In fact, the FDA has granted over 99 
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percent of requests for expanded access since 2009.37 Further, as previously stated the FDA has 
the power to prevent states from using right-to-laws through its federal pre-emption authority.38  
The requirements stated under the compassionate use provision are not overly 
burdensome and the proper route to obtain access to experiment treatment, in order to preserve 
the safety of patients.  Under expanded access, patients must either have an “immediately life-
threatening disease or condition or a serious disease” to qualify for compassionate use.39 
Determining whether a patient falls under the serious or immediately life-threatening disease or 
condition definition is based upon the information provided by the treating physician to the FDA, 
and is the first step in the FDA approval process.40 A patient with a life expectancy of no more 
than a few months, or who is likely to experience premature death is deemed to have a life 
threatening disease under the statute.41 A treating physician uses his or her clinical judgment to 
assess and determine the severity of a patient’s condition, and possible treatment options.42 
Factors such as impact on day-to-day life, chances of survival, or probability of the disease or 
condition worsening if left untreated are all considered when determining whether a patient 
qualifies for compassionate use.43  
 Next the FDA must determine whether the potential benefit of use of drug/treatment is 
warranted in light of the potential risk of harm to the patient under the given circumstances.44 
Finally, compassionate use of the drug cannot interfere with ongoing or the completion of 
clinical investigations to support marketing approval for expanded access use.45  
 The requirements of compassionate use are similar to the requirements stated under many 
state right-to-try laws. In response to public criticism of the lengthy approval process, the FDA 
has proposed a streamlined application process for individual patients. Form 3926 is expected to 
reduce the application completion time from 8 hours to 45 minutes.46  Draft Form 3926 is no 
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more than two pages long and is filled out by the treating physician (also referred to as a 
sponsor-investigator) on behalf of the patient.47 Once a complete 3926 Form has been submitted, 
the FDA will assign an individual patient investigational new drug (“IND”) number that either 
allows use of the investigational treatment or places the application on clinical hold.48 A decision 
from the FDA is projected to take no longer than 30 days once a complete 3926 is received.49 In 
cases of emergency, a treating physician may submit a request for access to investigational drug 
via telephone and, if approved, will also receive approval via telephone, allowing for an even 
quicker response time.50 These changes offer patients faster access to experimental treatment, but 
still provide patient safety.  
FDA regulations governing clinical trials for investigational new drug approval follow a 
rigorous set of requirements, which include three phases of clinical trials and legal informed 
consent from participants.51  The arduous process can be attributed to the legal response to past 
abuses suffered by research participants in early, unethical medical experiments such as the 
Tuskegee Syphilis Study and the Guatemala Experiment.52 The FDA’s goal is to ensure 
participant safety to prevent future abuses, while allowing the continuous follow of medical 
advancement.53 Investigators and researchers are responsible for disclosing risk to participants as 
part of the informed consent process.54 The compassionate use provision, in accord with the 
requirements under the IND clinical trial requirements, mandates that the physician authorizing 
use of the experiment drug “determine that the probable risk to the patient using the drug is not 
more than the probable risk from the disease.”55 Furthermore, the FDA requires sufficient 
evidence of the “safety and effectiveness” of the investigational drug in order to be used under 
expanded access.56 
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 The FDA compassionate use provision also contains safeguards that establish 
accountability for the sponsor (the individual or entity submitting application), investigator 
(treating physician), and sponsor-investigation (physician who submits application and treats 
patient).57  Manufacturers are permitted to collect the cost of manufacturing the drug if they grant 
patient access to the investigational drug, however, they are still subject to FDA oversight, which 
ensures a level of accountability not found under state right to try laws.58  Given, the FDA’s 
resources and expertise it is clear they are better equipped to make the final determination for 
patient experimental drug access. 
 Although state level involvement has bolstered terminally ill patients’ claims to speedier 
access to potentially lifesaving treatment, the FDA was and still is the best-suited regulatory 
authority to oversee the patient approval process to prevent harm to these patients in the future. 
While the right to try law movement has forced the FDA to revamp its current expand access 
provision, right to try laws are ultimately ineffective.  
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